According to the new law passed by the Colorado government doctors can prescribe medical marijuana for patients suffering from cancer, HIV and AIDS, glaucoma, PTSD or other chronic medical condition that causes, nausea, severe pain, and seizures. The new law includes all medical conditions in which opioids could be recommended.
My mom has a strange type of glaucoma. She said it is Uvietis caused by glaucoma. And it has to do something about the pressure of her eye being too low or high. (Not sure which)
And she asked her Dr. about medical marijuana and the doctor said that it might make it worse. Im not sure if her Dr is lieing to her or not..
Anyone know about this?
Some cannabinoid agonists (WIN 55212-2, anandamide) have demonstrated, in experimental studies, to act as ideal drugs in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells. Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.
aha, finally something tells you what they made eye drops from. of course this is a spanish>english machine translated scientific document , so there maybe errors and you should translate the page yourself before putting anything in your eye.
Topical application of cannabinoids
Due to the high lipid solubility, and the need to employ lipophilic products for proper dissolution, many vehicles have been tested, such as ethanol, dimethyl sulfoxide, polivinilpyrrolidone, Tween 80, Cremophor, emulphor, bovine serum albumin (BSA), 2-hydroxypropyl -β-ciclodextrino, and currently, it has been popularized Tocrisolve employing TM 67. the TM is a registered Tocrisolve preparation consisting of a vehicle designed for lipophilic compounds, such as cannabinoid and vanilloid agonists. The Tocrisolve TM consists of soybean oil in a ratio of 1:4 with water and is emulsified with the copolymer pluronic F68. Allows dissolve WIN 55212-2 to a concentration of 2%. On the other hand does not require the use of ethanol to promote your solution and has demonstrated a sustained ocular penetration agonist WIN 55212-2 dissolved therein applied topically after 68.
The Δ9-THC, dissolved in mineral oil, was shown to reduce the intraocular pressure equal to or higher than that obtained by pilocarpine (52% reduction), with a more prolonged effect 38,68. This hypotensive effect has been reproduced in other studies with different cannabinoids ( Table 2 ).
Topical application of Δ9-THC, CBN and CBD has been associated with mydriasis, conjunctival hyperemia, chemosis, severe cases of corneal opacification and neurotoxicity 70. Other ocular side effects associated with systemic administration routes are cannabinoids decrease in tear production, diplopia, accommodation disturbances, photophobia, nystagmus and blepharospasm 7,10,66,70.
The use of new solvents such as Tocrisolve TM and the 2-hydroxypropyl-β-ciclodextrino allowed correct cannabinoies dissolving and preparing solutions suitable for ocular application. Although the results to date are promising for application in the field of glaucoma, more safety studies and clinical trials are still necessary to examine the usefulness of these compounds in the treatment of glaucoma in our clinic daily.
After ten years of continuous and diligent research, pharmacologist,
Professor Manley West and ophthalmologist, Dr. Albert Lockhart
developed an eye drop, Canasol, specifically to treat the eye disease,
glaucoma. Glaucoma is estimated to affect 3% of the Jamaican population
and causes pain, visual disturbances and even blindness.
BREAKTHROUGH IN GLAUCOMA THERAPY
The drug was an important breakthrough, because it is derived from ganja,
Cannabis sativa, and was the first eye medication in the Caribbean to be
developed at UWI, Mona for this disease. Canasol has an important benefit
since it does not induce the negative side effects that are associated with
synthetic glaucoma therapies.
EARLY CLUES FROM FOLK MEDICINE
Professor West became interested in studying the ganja plant because he
had observed that country folk who used an eye wash made up of ganja in
water, always reported to him that it made them see better. The fishermen
who drank ganja ‘tea’ made the same claim and further claimed that their
vision at night was also better.
Dr. Albert Lockhart noted that his Rastafarian patients who used ganja had
a low incidence of glaucoma. More recently, he discovered that the eye
drop, Canasol, improves the integrity of the optic nerve, the nerve which
causes us to see, thus preventing blindness.
HELP FOR MOTION SICKNESS
As the researchers further investigated other properties of ganja, they dis-
covered its effectiveness against motion sickness. They developed the drug
Canavert, which specifically stabilizes the part of the brain that controls
motion sickness, thereby inhibiting vomiting and nausea that accompanies
this condition. However, the drug has not yet been prepared in commercial
RELIEF FOR BRONCHIAL ASTHMA
In the early 1990s, Professor West developed the drug, Asmasol, to treat
asthma, colds and the flu. The doctors now using this drug, report that
they prescribe it for children as well as adults, and that it is effective during
both the early and the late phases of the condition. Asmasol is a derivative
of ganja and is available in pharmacies throughout the Caribbean.
Professor Manley West is an emeritus Professor of Pharmacology in the
Faculty of Medical Sciences, UWI, Mona and the recipient of the Order of
Merit from the Government of Jamaica and the Gold Musgrave Medal from
the Institute of Jamaica for the development of Canasol. He also received
the Order of Merit from the Government of Canada for cardiovascular research.
Dr. Albert Lockhart received the Order of Merit from the Government of
Jamaica and the Gold Musgrave Medal from the Institute of Jamaica for the
development of Canasol.
who says marijuana does not work to reduce IOP in glaucoma?
This uncontrolled, unmasked, nonrandomized, prospec-tive study does not permit definitive conclusions about the
efficacy or toxicity of cannabinoids in the treatment of
glaucoma. There is an impression from this study that
treatment with oral THC lowered IOP in this group of
patients with end-stage open-angle glaucoma, but the
development of tolerance and the coexistence of signifi-cant systemic toxicity limited the potential usefulness of
this treatment. It was particularly impressive to the inves-tigators that throughout the study there was no observed
tendency for either the physicians or the patients to abuse
their access to cannabinoid derivatives. Furthermore, both
the patients and ophthalmologists greatly appreciated the
opportunity to participate in a study that gave them legal
access to cannabinoids as a last-resort treatment for end-stage glaucoma unresponsive to conventional treatments.
i do not understand why they talk about limited usefulness, the conventional medications had failed in these test subjects. it has tremendous usefulness for subjects where other medications do not work.
i do not understand why they talk about toxicity to oral thc.
All subjects experienced side effects during their
treatment with THC during this study (Table III). The
most commonly described toxic effects were dry mouth,
sleepiness, dizziness, depression, and confusion; these
effects were the same as those reported by other investi-gators.
18,19Although many of the side effects were consid-ered mild and were of little concern to subjects, other effects were very significant.